GILD Stock Risk & Deep Value Analysis
Gilead Sciences Inc
Healthcare • Drug Manufacturers - General
DVR Score
out of 10
What You Need to Know About GILD Stock
We analyzed Gilead Sciences Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran GILD through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
How Risky Is GILD Stock?
Overall Risk
Moderate
Financial Risk
Low
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for GILD?
- ⚠
Unfavorable clinical trial results for key pipeline assets
- ⚠
Increased competitive pressure in HIV and oncology markets
- ⚠
Regulatory setbacks or delays for new drug approvals
- ⚠
Macroeconomic pressures impacting drug pricing and access
Unlock GILD Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Gilead Sciences Inc (GILD) Do?
Market Cap
$152.30B
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
17,600
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Visit Gilead Sciences Inc WebsiteIs GILD Stock Undervalued?
Unlock the full AI analysis for GILD
Get the complete DVR score, risk analysis, and more
Is GILD Financially Healthy?
P/E Ratio
19.03
Does GILD Have a Competitive Moat?
Sign in to unlockMoat Rating
🏰 Wide
Moat Trend
Stable
Moat Sources
4 Identified
Gilead's moat is durable, primarily driven by its robust patent portfolio for key drugs, the high regulatory barriers to entry in pharmaceuticals, and significant R&D investment necessary to develop new innovative therapies.
Moat Erosion Risks
- •Patent expirations for blockbuster drugs, leading to generic competition
- •Failure of late-stage pipeline assets to meet clinical endpoints
- •Aggressive competitive launches from rivals with novel mechanisms of action
GILD Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive GILD Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings Report (Estimated early May 2026)
- •Additional regulatory approvals or label expansions for Trodelvy in new cancer indications
- •Clinical data updates for pipeline candidates in oncology and inflammation
Medium-Term (6-18 months)
- •Increased market penetration for Lenacapavir in HIV
- •Strategic partnerships to expand cell therapy manufacturing or geographic reach
- •Mid-stage clinical trial readouts for novel therapeutics (e.g., HBV/HDV programs)
Long-Term (18+ months)
- •Successful development and commercialization of next-generation oncology or inflammation therapies
- •Strategic M&A activity to expand into new high-growth therapeutic areas
- •Leadership in gene therapy or other disruptive biotechnologies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for GILD?
- ✓
Acceleration in Trodelvy sales growth beyond consensus estimates
- ✓
Positive clinical trial data for new pipeline compounds, particularly in oncology and inflammation
- ✓
Successful integration and performance of any new M&A targets
- ✓
Impact of HIV patent expirations on overall revenue growth
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for GILD (Gilead Sciences Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
